# Clinical Efficacy of MOAP Regimen for Relapsed/Refractory cHL as a Rescue Therapy After DP Regimen

> **NCT04026269** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Han weidong** · enrollment: 30 (estimated)

## Conditions studied

- Hodgkin Lymphoma

## Interventions

- **DRUG:** MOAP

## Key facts

- **NCT ID:** NCT04026269
- **Lead sponsor:** Han weidong
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-07-30
- **Primary completion:** 2020-12-31
- **Final completion:** 2020-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2019-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04026269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04026269, "Clinical Efficacy of MOAP Regimen for Relapsed/Refractory cHL as a Rescue Therapy After DP Regimen". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04026269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*